The diagnostic value of detecting the BRAF V600E mutation in AUS thyroid nodules lies in its high specificity for PTC. The presence of this mutation in AUS nodules strongly suggests malignancy, aiding in the stratification of patients for appropriate surgical intervention. Studies have shown that BRAF V600E is associated with more aggressive tumor phenotypes and resistance to radioiodine therapy, further underscoring its prognostic significance [11-13]. Here, BRAF is linked to thyroiditis.